1. Generics Bulletin
  2. >>Business
  3. >>Deals

Dong-A Makes Deal For Darbepoetin Alfa With Turkey’s Polifarma

Biosimilar Version Of Aranesp/Nesp Licensed For Turkey, Brazil And Mexico

 
• By Dave Wallace

Korean developer Dong-A has signed an exclusive licensing deal with Turkey’s Polifarma covering its darbepoetin biosimilar version of Aranesp/Nesp in Turkey, Brazil and Mexico.

Turkey flag
Polifarma’s Home Of Turkey is one of the three countries covered by the agreement • Source: Shutterstock

Korean biosimilars developer Dong-A ST has signed a licensing deal with Turkey’s Polifarma offering exclusive rights to its Aranesp/Nesp (darbepoetin biosimilar) biosimilar, DA-3880, in Turkey, Brazil and Mexico.

Dong-A said the deal formed part of its efforts aimed at “building a foundation for expanding its biosimilar business

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business